Leiomyosarcoma Clinical Trials in Boston, Massachusetts

4 studies are recruiting for leiomyosarcoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

   This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Dana-Farber/Harvard Cancer Center, Boston, Massachusetts

   Locations

   175 in total

   Run by

   European Organisation for Research and Treatment of Cancer - EORTC

   See if you can join NCT04031677 on ClinicalTrials.gov

2. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

   This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   10 in total

   Run by

   STORM Therapeutics LTD

   See if you can join NCT06975293 on ClinicalTrials.gov

3. NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

   The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, with or without RT. * To …

   Stage

   Phase 1

   Ages

   Up to 30

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   7 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06239272 on ClinicalTrials.gov

4. Metastatic Leiomyosarcoma Biomarker Protocol

   Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of m…

   Stage

   Not phased

   Ages

   Any age

   Site

   Dana- Farber, Boston, Massachusetts

   Locations

   11 in total

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT05653388 on ClinicalTrials.gov